Glycotest closes $3.22M first round, exits EMV Capital's balance sheet
What's the deal? Glycotest, a US liver-cancer diagnostics company, has closed a first tranche of funding worth roughly $3.22 million, led and syndicated by EMV CapitalDealroom has a profile for this one. Try Dealroom → Partners.
The early VC round included about $1.05 million in cash and $2.17 million from converted loans. EMV converted $0.97 million of its own convertible loan and kept a 48.67% stake.
That holding is now valued at £13.7 million, up 24.3% from £11 million at the end of 2025.
Why now? The raise triggers Glycotest's deconsolidation from EMV Capital as of June 30, 2026, meaning it is no longer a controlled subsidiary of the AIM-listed investment group.
The proceeds fund development of second-generation glycoproteomic assays with the University of Georgia, assaying over 1,300 clinical samples to validate its liver-cancer panel.
Glycotest is also preparing a CLIA-certified lab, targeting a 2027 commercial launch.
What could go wrong? The round is only a first close. Glycotest still has headroom to raise up to $1.95 million more within 120 days.
EMV also left $0.37 million of its convertible loan unconverted, a balance it may convert in later rounds. Diagnostics timelines are long, and the 2027 launch hinges on clinical validation and regulatory clearance holding to schedule.
The signal: The deal reflects EMV Capital's playbook as a deep tech and life sciences VC group, backing early-stage companies through convertible loans and then crystallising value as they mature toward commercial readiness. With Glycotest targeting a 2027 launch of blood tests for at-risk liver cancer populations, the deconsolidation lets EMV retain meaningful upside while shifting the diagnostics firm's funding burden onto a wider investor syndicate.
Read more: Investegate
Image credit: Generated with Gemini
